6 March, 2024 | Online

17:00-18:00 CET

Chairs: Prof. Elena Bargagli (Siena, Italy), Dr Anna Maria Hoffmann-Vold (Oslo, Norway)
Speakers: Dr George Margaritopoulos (Thessaloniki, Greece), Prof. Dr Britta Maurer (Bern, Switzerland), Prof. Vincent Cottin (Lyon, France)

Fees: Free for ERS members / €10 for non-members

Overview:

This webinar aims to discuss the current knowledge on autoimmune pulmonary alveolar proteinosis (PAP) and interstitial pneumonia with autoimmune features (IPAF) and highlight the need for a guideline document regarding the connective tissue disease associated interstitial lung disease (CTD-ILD) from the pneumologist and rheumatologist point of view.

Educational aims:

• Overview of the research entity IPAF, what is the current knowledge regarding the diagnosis, treatment and prognosis. Discussion on whether there is ground to switch the definition of IPAF from research to clinical entity.
• The diagnosis and treatment of CTD-ILDs poses significant difficulties in the everyday clinical practice of both pneumologists and rheumatologists. The need for a guideline document will be discussed by physicians from both specialties.

Topics

• IPAF: Is it a clinical diagnosis? - George Margaritopoulos
• Guidelines in CTD-ILD:

- The pulmonologist's view - Vincent Cottin
- The Rheumatologist's view - Britta Mauer

Target audience

• Pulmonologists
• Rheumatologists

Learning outcomes

The participants of the webinar will get information about whether the research entity of IPAF could be formally established as clinical entity and what will be the implications of this switch in the everyday clinical practice. Finally, the need of a formal guideline document on the diagnosis and management of CTD-ILDs will be discussed by the specialties involved in the management of these patients.